The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Hims & Hers may leverage FDA compounding exemptions to further extend its compounded GLP-1 offerings. Learn why HIMS stock is ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

Novo Nordisk’s amycretin shows 22% weight loss over 36 weeks, potentially surpassing Eli Lilly’s Zepbound. Further trials are ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

H.C. Wainwright adjusted its price target for Lexaria Bioscience (NASDAQ:LEXX) to $7.00, down from the previous target of $10.00, while maintaining a Buy rating on the company's shares. With the stock ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...